drugset / Trial / NCT04379518
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Phase 1/2
Terminated
4 enrolled
Roswell Park Cancer Institute
AIM ImmunoTech Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.
Timeline
- Start
- 2020-11-17
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Interferon Alfa-2b | Protein / enzyme biologic | 0 iu | Intravenous |
| Subject | Recombinant Interferon Alfa-2b | Protein / enzyme biologic | 5 iu | Intravenous |
| Subject | Recombinant Interferon Alfa-2b | Protein / enzyme biologic | 10 iu | Intravenous |
| Subject | Recombinant Interferon Alfa-2b | Protein / enzyme biologic | 20 iu | Intravenous |
| Subject | Rintatolimod | Oligonucleotide (other) | — | Intravenous |